Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Eastern Cooperative Oncology Group
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier:
NCT02085408
First received: March 11, 2014
Last updated: September 16, 2014
Last verified: September 2014
  Purpose

This randomized phase III trial studies clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as clofarabine, daunorubicin hydrochloride, cytarabine, and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. It is not yet known which chemotherapy regimen is more effective in treating acute myeloid leukemia.


Condition Intervention Phase
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Erythroleukemia (M6a)
Adult Pure Erythroid Leukemia (M6b)
Secondary Acute Myeloid Leukemia
Untreated Adult Acute Myeloid Leukemia
Drug: clofarabine
Drug: daunorubicin hydrochloride
Other: clinical observation
Drug: cytarabine
Drug: decitabine
Other: laboratory biomarker analysis
Procedure: quality-of-life assessment
Other: questionnaire administration
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Resource links provided by NLM:


Further study details as provided by Eastern Cooperative Oncology Group:

Primary Outcome Measures:
  • Overall survival [ Time Frame: Time between randomization and death from any cause, assessed up to 5 years ] [ Designated as safety issue: No ]
    Due to the potential confounding by maintenance therapy on the induction comparison, a weighted analysis (weighted Cox regression) will be used for the primary analysis.


Secondary Outcome Measures:
  • Mortality rate [ Time Frame: 30 days ] [ Designated as safety issue: No ]
  • Induction complete response rates [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    The induction response (CR + CRi) rates will be compared between the clofarabine arm and the standard treatment arm. At the end of the study, the 95% confidence interval on the difference in the CR + CRi rates (CR + CRi rate of standard treatment - CR + CRi rate of clofarabine) will be computed based on the normal approximation to the difference of two independent binomial proportions.

  • Disease-free survival (DFS) [ Time Frame: Time from the second randomization to relapse or death without relapse, assessed up to 5 years ] [ Designated as safety issue: No ]
    The primary analysis of DFS will use a one-sided log rank test stratified on the induction therapy and on patient age and cytogenetics to determine the effect of decitabine on DFS as a maintenance therapy in comparison with observation.

  • Overall survival [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    To evaluate the impact of consolidation with non-ablative conditioning and allogeneic hematopoietic stem cell transplantation with an HLA-identical sibling on overall survival in patients who achieve a 'morphologic leukemia-free state, a one-sided log rank test stratified on age, therapy-related AML, the presence of AHD at the time of diagnosis of AML, and the induction therapy they received will be used.

  • Epidemiological factors, measured using the Acute Leukemia Epidemiology and Survival in ECOG (ALESE) questionnaire [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    The proportions of obese patients and patients who had benzene exposure, ever smoked in their lifetime, took aspirin regularly, took acetaminophen regularly, ever lived in rural/farm environments, or had other exposures or lifestyle factors will be calculated separately, along with their 95% confidence intervals.

  • Change in the Functional Assessment of Cancer Therapy (FACT)-Leukemia-specific (Leu) Trial Outcome Index (TOI) score [ Time Frame: Baseline to 30 days after beginning induction therapy ] [ Designated as safety issue: No ]
    Descriptive statistics will be provided and Cronbach's alpha will be calculated at each time point to assess reliability. Repeated measures analysis techniques will also be utilized to examine the treatment effect and time effect on FACT-Leu TOI score. For patients randomized to the induction treatments, the longitudinal scores collected from time of randomization, two weeks after beginning induction therapy (at the time of nadir), and at 28-30 days after beginning induction therapy, will be analyzed according to the methods described in Schluchter and Schluchter, Greene and Beck.

  • Change in the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue score [ Time Frame: Baseline to 30 days after beginning induction therapy ] [ Designated as safety issue: No ]
    Descriptive statistics will be provided and Cronbach's alpha will be calculated at each time point to assess reliability. Repeated measures analysis techniques will also be utilized to examine the treatment effect and time effect on FACIT Fatigue score. For patients randomized to the induction treatments, the longitudinal scores collected from time of randomization, two weeks after beginning induction therapy (at the time of nadir), and at 28-30 days after beginning induction therapy, will be analyzed according to the methods described in Schluchter and Schluchter, Greene and Beck.


Other Outcome Measures:
  • Epigenetic signatures, determined by expression and methylation profiling [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    The methods described in Thompson et.al will be used to identify epigenetics signatures which are different between patients who relapsed and patients who did not relapse. Signatures identified by epigenetic analysis will be correlated with DFS using a least angle regression and shrinkage (LARS)/least absolute shrinkage and selection operator (LASSO) approach for each maintenance arm.

  • Gene expression levels [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Genes will be filtered by examining ratios of standard deviation to the mean. Genes will be hierarchically clustered to find genes with high/low fold change/differences. Supervised analyses will be used to identify genes that are differentially expressed between patients who relapsed and patients who did not relapsed. Genes or epigenetic signatures identified by gene expression or epigenetic analysis will be correlated with DFS using LARS/LASSO approach.

  • Predictive mutations [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    For each mutation a stratified log-rank test will be performed (using the strata at randomization) adjusted for multiple testing using resampling and the min-p method of Westfall and Young as implemented in the R package multtest. In addition tests for interaction between treatment assignment and mutational status will be performed to identify potential predictive mutations. The prognostic relevance of known mutations on overall survival and response to therapy will be assessed, and novel mutations identified in discovery studies and by other efforts will also be included.

  • Prognostic risk groups [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Prognostic risk groups will be identified by using recursive partitioning and logistic regression, both of which are highly suitable for binary predictors. A randomly chosen subsample of 423 (2/3 of 635) patients will be used for training these models and the remaining 212 for validation.

  • Pgp levels [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    The possible association of response to clofarabine with Pgp will be explored using a Wilcoxon rank-sum test.

  • CXCR4 expression levels [ Time Frame: Up to 5 years ] [ Designated as safety issue: No ]
    Expression intensity of CXCR4 will be divided into three groups (low, intermediate, high). The grading will be further simplified as high/intermediate vs. low. Data will be first analyzed by induction treatment arms. When data are available, logistic and Cox regression analysis, adjusted by treatment effect and prognostic factors (including cytogenetics), will be used to assess whether CXCR4 expression level is an independent predictor for response or survival.


Estimated Enrollment: 747
Study Start Date: December 2010
Estimated Primary Completion Date: February 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm I (daunorubicin hydrochloride and cytarabine)
See Detailed Description
Drug: daunorubicin hydrochloride
Given IV
Other Names:
  • Cerubidin
  • Cerubidine
  • daunomycin hydrochloride
  • daunorubicin
  • RP-13057
Other: clinical observation
Undergo clinical observation
Other Name: observation
Drug: cytarabine
Given IV
Other Names:
  • ARA-C
  • arabinofuranosylcytosine
  • arabinosylcytosine
  • Cytosar-U
  • cytosine arabinoside
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Other: questionnaire administration
Ancillary studies
Experimental: Arm II (clofarabine)
See Detailed Description
Drug: clofarabine
Given IV
Other Names:
  • CAFdA
  • Clofarex
  • Clolar
Drug: decitabine
Given IV
Other Names:
  • 5-aza-dCyd
  • 5AZA
  • DAC
Other: laboratory biomarker analysis
Correlative studies
Procedure: quality-of-life assessment
Ancillary studies
Other Name: quality of life assessment
Other: questionnaire administration
Ancillary studies

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Sexually active males must be strongly advised to use an accepted and effective method of contraception
  • Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1
  • Total bilirubin =< grade 1

    • Note: If total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
  • Patient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS])
  • Patient must not have an active, uncontrolled infection
  • ADDITIONAL INDUCTION ELIGIBILITY CRITERIA:
  • Newly-diagnosed AML patients according to World Health Organization (WHO) classification who are considered candidates for intensive chemotherapy based upon examination of peripheral blood or bone marrow aspirate specimens or touch preparations of the bone marrow biopsy obtained within two weeks prior to randomization; a bone marrow aspirate is required for enrollment; however, on occasion there is discordance between percentage of myeloblasts on the differential of the peripheral blood or aspirate; the peripheral blood criteria are sufficient for diagnosis; confirmatory immunophenotyping will be performed centrally

    • NOTE: patients must be registered to E3903 (Ancillary Laboratory Protocol for the Collection of Diagnostic Material on Patients Considered for Eastern Cooperative Oncology Group (ECOG) Treatment Trials for Leukemia or Related Hematologic Disorders) and must undergo eligibility testing for the study by multiparameter flow cytometry
    • NOTE: Southwest Oncology Group (SWOG)/Cancer Trials Support Unit (CTSU) institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906
  • ECOG performance status (PS) 0-3 (restricted to ECOG PS 0-2 if >= 70 years of age)
  • Patients with acute promyelocytic leukemia (APL) confirmed either by the presence of t(15;17)(q22;q21) or promyelocytic leukemia (PML)/retinoic acid receptor (RAR) alpha transcripts will be excluded
  • Patients must not have blastic transformation of chronic myelogenous leukemia
  • Patients with secondary AML are eligible for enrollment onto the trial; secondary AML is defined as AML that has developed in a person with a history of antecedent blood count abnormalities, or myelodysplastic syndrome (MDS), or a myeloproliferative disorder (excluding chronic myeloid leukemia); or a history of prior chemotherapy or radiation therapy for a disease other than AML

    • NOTE: Prior therapy of MDS with decitabine, low-dose cytarabine, or azacitidine is excluded
  • Patients may not have received prior chemotherapy for AML with the exception of hydroxyurea for increased blast count or leukapheresis for leukocytosis
  • Total serum bilirubin =< 1.5 times upper limit of normal (ULN) (=< grade 1); if total bilirubin is 2 to 3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
  • Patients with a serum creatinine > 1 are eligible if they have a calculated glomerular filtration rate (GFR) of >= 60 ml/min (i.e. class I or class II chronic kidney disease ) using the Modification of Diet in Renal Disease (MDRD) formula

    • Note: Daily creatinine and MDRD formula are only for the 1st induction cycle
  • Cardiac ejection fraction >= 45% or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a two-dimensional (2-D) echocardiogram (ECHO) scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to receiving treatment

    • NOTE: when a multi gated acquisition scan (MUGA) or echocardiogram cannot be obtained due to weekend or holiday, then patients may be enrolled provided there is no history of significant cardiovascular disease and a measurement of cardiac ejection fraction will be performed within 5 days of study enrollment
  • Patients with suspected central nervous system (CNS) involvement should undergo lumbar puncture; those with documented CNS involvement will be excluded
  • Cytogenetic analysis must be performed from diagnostic bone marrow (preferred) or if adequate number of circulating blasts (>10^9/l) from peripheral blood; this must be done via E3903

    • NOTE: SWOG/CTSU institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906
  • Patients who have received previous treatment for antecedent hematological disorders (AHD) with 5-azacitidine, decitabine, or low dose cytarabine will be excluded
  • Patients with known human immunodeficiency virus (HIV) infection are excluded
  • HLA typing should be performed at registration, if possible
  • Diagnostic bone marrow and peripheral blood specimens must be submitted for immunophenotyping and selected molecular testing; this must be done via E2906

    • NOTE: SWOG/CTSU institutions: E3903 is not open at the CTSU; therefore, baseline submissions must be submitted on E2906
  • CONSOLIDATION CRITERIA:
  • NOTE: All patients achieving CR or complete remission with incomplete blood count recovery (CRi) will receive consolidation when fit
  • NOTE: Patients proceeding to transplant are allowed up to one cycle of consolidation treatment
  • Consolidation cycle 1 must commence within sixty days of the bone marrow aspirate and biopsy that confirmed the presence of a CR or CRi
  • Patients must have achieved a CR or CRi (or morphologic leukemia-free state for those patients proceeding to Arm G transplant)
  • Patients who have achieved a CR or CRi must have maintained peripheral blood evidence of a CR or CRi
  • Patients must have an ECOG performance status of 0-2
  • Patients must have resolved any serious infectious complications related to induction

    • NOTE: Patients with an HLA-matched donor and proceeding to transplant will be allowed up to one cycle of consolidation treatment
  • Any significant medical complications related to induction must have resolved
  • Patients must have a creatinine and AST =< grade 1
  • MAINTENANCE CRITERIA:
  • Maintenance should commence within 60 days of recovery of peripheral blood counts after consolidation cycle 2; patients must begin consolidation cycle 2 within 60 days of recovery to be eligible for further therapy
  • Patients must have maintained peripheral blood evidence of a remission and must have a CR or CRi, confirmed on restaging bone marrow (BM) aspirate and biopsy and cytogenetic analysis
  • Patients must have an ECOG performance status of 0 -2
  • Patients must have resolved any serious infectious complications related to consolidation cycle 2
  • Any significant medical complications related to consolidation cycle 2 must have resolved
  • Total serum bilirubin =< 1.5 x ULN

    • NOTE: if total bilirubin is 2-3 mg/dL, but direct bilirubin is normal, then the patient will be considered eligible
  • Serum creatinine =< grade 1
  • The absolute neutrophil count (ANC) must be > 1000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover
  • The platelet count must be > 75,000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recover
  • ALLOGENEIC TRANSPLANTATION:
  • Patients must be > 30 days and < 90 days from the start of induction or re-induction chemotherapy, or > 30 days and < 90 days of recovery from consolidation cycle 1 (if received), and must have achieved a response to induction therapy (CR, CRi, or "morphologic disease-free state", documented > 27 days after start of most-recent chemotherapy)
  • Patients must have recovered from the effects of induction, re-induction, or consolidation chemotherapy (all toxicities =< grade I with the exception of reversible electrolyte abnormalities), and have no ongoing active infection requiring treatment
  • Patients must have a total serum bilirubin =< 1.5 x ULN (grade =< 1) and a serum creatinine =< grade 1
  • An eligible HLA-identical donor (either related or unrelated) should be available; in sibling donors, low resolution HLA typing (A,B,DR) will be considered sufficient; in the case of unrelated donors, high-resolution class I and II typing (A, B, C, DRB1 and DQ) should be matched at all 10 loci; donors must be willing and able to undergo peripheral blood progenitor mobilization

    • HLA-identical sibling (6/6): the donor must be determined to be an HLA-identical sibling (6/6) by serologic typing for class (A, B) and low resolution molecular typing for class II (DRB1)
    • Matched unrelated donor (10/10): high resolution molecular typing at the following loci is required: HLA-A, -B, -C, -DRBL, and -DQB1
    • NOTE: for matched donors - will allow select 1 antigen mismatched sibling donors and unrelated donors in accordance with site institutional standard, as long as matched at HLA-A, HLA-B, HLA-C, and DRB1, and with advanced discussion/approval by the Study Chair and the bone marrow transplant (BMT) co-chair
  • Patients must be considered reliable enough to comply with the medication regimen and follow-up, and have social support necessary to allow this compliance
  • Patients must have a cardiac ejection fraction of >= 40%, or within institutional normal limits; a nuclear medicine gated blood pool examination is preferred; a 2-D ECHO scan is acceptable if a calculated ejection fraction is obtained and follow-up measurement of the cardiac ejection fraction will also be performed by echocardiography; measurement of cardiac ejection fraction should be within two weeks prior to allogeneic transplantation
  • Diffusion capacity of carbon monoxide (DLCO) > 40% with no symptomatic pulmonary disease
  • No known hypersensitivity to Escherichia (E.) coli-derived products
  • No human immunodeficiency virus (HIV) infection; patients with immune dysfunction are at a significantly higher risk of toxicities from intensive immunosuppressive therapies
  • Creatinine =< grade 1
  • Bilirubin =< grade 1

    • If bilirubin is 2-3 mg/dL, but direct bilirubin is normal then patient will be considered eligible
  • AST =< grade 1
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02085408

  Hide Study Locations
Locations
United States, Alabama
University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Contact: Carla I. Falkson    205-934-0309      
Principal Investigator: Carla I. Falkson         
United States, Arizona
Mayo Clinic in Arizona Recruiting
Scottsdale, Arizona, United States, 85259
Contact: James M. Foran    507-538-7623      
Principal Investigator: James M. Foran         
Arizona Cancer Center at University Medical Center North Recruiting
Tucson, Arizona, United States, 85719
Contact: Faiz Anwer    520-626-9008      
Principal Investigator: Faiz Anwer         
University of Arizona Health Sciences Center Recruiting
Tucson, Arizona, United States, 85724
Contact: Faiz Anwer    520-626-9008      
Principal Investigator: Faiz Anwer         
United States, Colorado
The Medical Center of Aurora Recruiting
Aurora, Colorado, United States, 80012
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Boulder Community Hospital Active, not recruiting
Boulder, Colorado, United States, 80301
Penrose-Saint Francis Healthcare Recruiting
Colorado Springs, Colorado, United States, 80907
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Exempla Saint Joseph Hospital Recruiting
Denver, Colorado, United States, 80218
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Colorado Cancer Research Program CCOP Recruiting
Denver, Colorado, United States, 80224-2522
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Saint Anthony Central Hospital Recruiting
Denver, Colorado, United States, 80204
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
Porter Adventist Hospital Recruiting
Denver, Colorado, United States, 80210
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Rose Medical Center Recruiting
Denver, Colorado, United States, 80220
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Presbyterian - Saint Lukes Medical Center - Health One Recruiting
Denver, Colorado, United States, 80218
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Swedish Medical Center Recruiting
Englewood, Colorado, United States, 80110
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
North Colorado Medical Center Recruiting
Greeley, Colorado, United States, 80631
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Littleton Adventist Hospital Recruiting
Littleton, Colorado, United States, 80122
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Sky Ridge Medical Center Recruiting
Lone Tree, Colorado, United States, 80124
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Longmont United Hospital Recruiting
Longmont, Colorado, United States, 80501
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
McKee Medical Center Recruiting
Loveland, Colorado, United States, 80539
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Parker Adventist Hospital Recruiting
Parker, Colorado, United States, 80138
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
Saint Mary Corwin Medical Center Recruiting
Pueblo, Colorado, United States, 81004
Contact: Keren Sturtz    888-785-6789      
Principal Investigator: Keren Sturtz         
North Suburban Medical Center Active, not recruiting
Thornton, Colorado, United States, 80229
Exempla Lutheran Medical Center Recruiting
Wheat Ridge, Colorado, United States, 80033
Contact: Eduardo R. Pajon    888-785-6789      
Principal Investigator: Eduardo R. Pajon         
United States, Connecticut
Saint Francis Hospital and Medical Center Recruiting
Hartford, Connecticut, United States, 06105
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
The Hospital of Central Connecticut Recruiting
New Britain, Connecticut, United States, 06050
Contact: Brian J. Byrne    860-224-5660      
Principal Investigator: Brian J. Byrne         
United States, Delaware
Beebe Medical Center Recruiting
Lewes, Delaware, United States, 19958
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
Christiana Care Health System-Christiana Hospital Recruiting
Newark, Delaware, United States, 19718
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
United States, Florida
University of Florida Recruiting
Gainesville, Florida, United States, 32610
Contact: Jack W. Hsu    352-273-8675    trials@cancer.ufl.edu   
Principal Investigator: Jack W. Hsu         
Mayo Clinic in Florida Recruiting
Jacksonville, Florida, United States, 32224-9980
Contact: James M. Foran    507-538-7623      
Principal Investigator: James M. Foran         
Florida Hospital Recruiting
Orlando, Florida, United States, 32803
Contact: Lee M. Zehngebot    407-303-5623      
Principal Investigator: Lee M. Zehngebot         
United States, Georgia
Piedmont Hospital Recruiting
Atlanta, Georgia, United States, 30309
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Atlanta Regional CCOP Recruiting
Atlanta, Georgia, United States, 30342
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Saint Joseph's Hospital of Atlanta Recruiting
Atlanta, Georgia, United States, 30342
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Northside Hospital Recruiting
Atlanta, Georgia, United States, 30342
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Georgia Regents University Recruiting
Augusta, Georgia, United States, 30912
Contact: Sharad A. Ghamande    706-721-1663    cancer@georgiahealth.edu   
Principal Investigator: Sharad A. Ghamande         
Well Star Cobb Hospital Recruiting
Austell, Georgia, United States, 30106
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
John B Amos Cancer Center Recruiting
Columbus, Georgia, United States, 31904
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Dekalb Medical Center Recruiting
Decatur, Georgia, United States, 30033
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Piedmont Fayette Hospital Recruiting
Fayetteville, Georgia, United States, 30214
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Gwinnett Medical Center Recruiting
Lawrenceville, Georgia, United States, 30045
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Wellstar Kennestone Hospital Recruiting
Marietta, Georgia, United States, 30060
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Southern Regional Medical Center Recruiting
Riverdale, Georgia, United States, 30274
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
Harbin Clinic Medical Oncology and Clinical Research Recruiting
Rome, Georgia, United States, 30165
Contact: Thomas E. Seay    404-303-3355      
Principal Investigator: Thomas E. Seay         
United States, Hawaii
Oncare Hawaii Inc - Kapiolani Medical Center at Pali Momi Recruiting
Aiea, Hawaii, United States, 96701
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Kapiolani Medical Center at Pali Momi Recruiting
Aiea, Hawaii, United States, 96701
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Kapiolani Medical Center for Women and Children Recruiting
Honolulu, Hawaii, United States, 96826
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Kuakini Medical Center Recruiting
Honolulu, Hawaii, United States, 96817
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
OnCare Hawaii-Liliha Recruiting
Honolulu, Hawaii, United States, 96817-3169
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Oncare Hawaii Inc-POB II Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Oncare Hawaii Inc-Kuakini Recruiting
Honolulu, Hawaii, United States, 96817
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
University of Hawaii Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Queen's Medical Center Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Straub Clinic and Hospital Recruiting
Honolulu, Hawaii, United States, 96813
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Castle Medical Center Recruiting
Kailua, Hawaii, United States, 96734
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
Wilcox Memorial Hospital and Kauai Medical Clinic Recruiting
Lihue, Hawaii, United States, 96766
Contact: Jeffrey L. Berenberg    808-586-2979      
Principal Investigator: Jeffrey L. Berenberg         
United States, Idaho
Saint Alphonsus Regional Medical Center Recruiting
Boise, Idaho, United States, 83706
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
United States, Illinois
Saint Anthony's Health Active, not recruiting
Alton, Illinois, United States, 62002
Saint Joseph Medical Center Recruiting
Bloomington, Illinois, United States, 61701
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Bloomington Recruiting
Bloomington, Illinois, United States, 61701
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Graham Hospital Association Active, not recruiting
Canton, Illinois, United States, 61520
Illinois CancerCare-Canton Recruiting
Canton, Illinois, United States, 61520
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Memorial Hospital Active, not recruiting
Carthage, Illinois, United States, 62321
Illinois CancerCare-Carthage Recruiting
Carthage, Illinois, United States, 62321
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Mount Sinai Hospital Medical Center Recruiting
Chicago, Illinois, United States, 60608
Contact: Pam G. Khosla    773-257-5960    suhi@sinai.org   
Principal Investigator: Pam G. Khosla         
Hematology and Oncology Associates Terminated
Chicago, Illinois, United States, 60611
University of Illinois Recruiting
Chicago, Illinois, United States, 60612
Contact: John G. Quigley    312-355-3046      
Principal Investigator: John G. Quigley         
Decatur Memorial Hospital Recruiting
Decatur, Illinois, United States, 62526
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
Eureka Hospital Active, not recruiting
Eureka, Illinois, United States, 61530
Illinois CancerCare-Eureka Recruiting
Eureka, Illinois, United States, 61530
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare Galesburg Recruiting
Galesburg, Illinois, United States, 61401
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Western Illinois Cancer Treatment Center Recruiting
Galesburg, Illinois, United States, 61401
Contact: John G. Quigley    312-355-3046      
Principal Investigator: John G. Quigley         
Mason District Hospital Active, not recruiting
Havana, Illinois, United States, 62644
Illinois CancerCare-Havana Active, not recruiting
Havana, Illinois, United States, 62644
Hematology Oncology Associates of Illinois-Highland Park Recruiting
Highland Park, Illinois, United States, 60035
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Hinsdale Hematology Oncology Associates Incorporated Recruiting
Hinsdale, Illinois, United States, 60521
Contact: Elyse Schneiderman    630-654-1790    info@hhoaltd.com   
Principal Investigator: Elyse Schneiderman         
Presence Saint Mary's Hospital Recruiting
Kankakee, Illinois, United States, 60901
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Illinois CancerCare-Kewanee Clinic Recruiting
Kewanee, Illinois, United States, 61443
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
North Shore Hematology Oncology Recruiting
Libertyville, Illinois, United States, 60048
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Mcdonough District Hospital Recruiting
Macomb, Illinois, United States, 61455
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Macomb Recruiting
Macomb, Illinois, United States, 61455
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Loyola University Medical Center Recruiting
Maywood, Illinois, United States, 60153
Contact: Kathleen W. Phelan    708-226-4357      
Principal Investigator: Kathleen W. Phelan         
Holy Family Medical Center Recruiting
Monmouth, Illinois, United States, 61462
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Monmouth Recruiting
Monmouth, Illinois, United States, 61462
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Good Samaritan Regional Medical Center Withdrawn
Mt. Vernon, Illinois, United States, 62864
Illinois Cancer Specialists-Niles Recruiting
Niles, Illinois, United States, 60714
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Illinois CancerCare-Community Cancer Center Active, not recruiting
Normal, Illinois, United States, 61761
Bromenn Regional Medical Center Active, not recruiting
Normal, Illinois, United States, 61761
Community Cancer Center Foundation Recruiting
Normal, Illinois, United States, 61761
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Ottawa Regional Hospital and Healthcare Center Recruiting
Ottawa, Illinois, United States, 61350
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Ottawa Clinic Recruiting
Ottawa, Illinois, United States, 61350
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Pekin Recruiting
Pekin, Illinois, United States, 61603
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Pekin Cancer Treatment Center Recruiting
Pekin, Illinois, United States, 61554
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
OSF Saint Francis Medical Center Recruiting
Peoria, Illinois, United States, 61637
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois Oncology Research Association CCOP Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Methodist Medical Center of Illinois Recruiting
Peoria, Illinois, United States, 61603
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Proctor Hospital Recruiting
Peoria, Illinois, United States, 61614
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peoria Recruiting
Peoria, Illinois, United States, 61615
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois CancerCare-Peru Recruiting
Peru, Illinois, United States, 61354
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Illinois Valley Hospital Recruiting
Peru, Illinois, United States, 61354
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Perry Memorial Hospital Active, not recruiting
Princeton, Illinois, United States, 61356
Illinois CancerCare-Princeton Recruiting
Princeton, Illinois, United States, 61356
Contact: Nguyet A. Le-Lindqwister    800-793-2262      
Principal Investigator: Nguyet A. Le-Lindqwister         
Swedish American Hospital Terminated
Rockford, Illinois, United States, 61104
Hematology Oncology Associates of Illinois - Skokie Recruiting
Skokie, Illinois, United States, 60076
Contact: Jessica K. Altman    312-695-1301    cancer@northwestern.edu   
Principal Investigator: Jessica K. Altman         
Illinois CancerCare-Spring Valley Active, not recruiting
Spring Valley, Illinois, United States, 61362
Memorial Medical Center Recruiting
Springfield, Illinois, United States, 62781-0001
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
United States, Indiana
Saint Francis Hospital and Health Centers Recruiting
Beech Grove, Indiana, United States, 46107
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Fort Wayne Medical Oncology and Hematology Inc - State Boulevard Recruiting
Fort Wayne, Indiana, United States, 46845
Contact: Sreenivasa R. Nattam    260-484-8830    ledgar@fwmoh.com   
Principal Investigator: Sreenivasa R. Nattam         
Franciscan St. Francis Health Recruiting
Indianapolis, Indiana, United States, 46237
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Reid Hospital and Health Care Services Recruiting
Richmond, Indiana, United States, 47374
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
United States, Iowa
McFarland Clinic Recruiting
Ames, Iowa, United States, 50010
Contact: Joseph J. Merchant    515-239-2621      
Principal Investigator: Joseph J. Merchant         
Mercy Medical Center-Sioux City Recruiting
Sioux City, Iowa, United States, 51104
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Saint Luke's Regional Medical Center Recruiting
Sioux City, Iowa, United States, 51104
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
Siouxland Hematology Oncology Associates Recruiting
Sioux City, Iowa, United States, 51101
Contact: Donald B. Wender    712-252-0088      
Principal Investigator: Donald B. Wender         
United States, Kentucky
University of Kentucky Recruiting
Lexington, Kentucky, United States, 40536
Contact: Dianna S. Howard    859-257-3379      
Principal Investigator: Dianna S. Howard         
Norton Health Care Pavilion - Downtown Recruiting
Louisville, Kentucky, United States, 40202
Contact: Don A. Stevens    502-629-2500      
Principal Investigator: Don A. Stevens         
United States, Louisiana
Ochsner Clinic Foundation-Baton Rouge Recruiting
Baton Rouge, Louisiana, United States, 70809
Contact: Robert V. Emmons    888-562-4763      
Principal Investigator: Robert V. Emmons         
Ochsner Clinic Foundation Recruiting
New Orleans, Louisiana, United States, 70121
Contact: Robert V. Emmons    888-562-4763      
Principal Investigator: Robert V. Emmons         
Ochsner Baptist Medical Center Recruiting
New Orleans, Louisiana, United States, 70115
Contact: Robert V. Emmons    888-562-4763      
Principal Investigator: Robert V. Emmons         
United States, Maine
Harold Alfond Center for Cancer Care Recruiting
Augusta, Maine, United States, 04330
Contact: Thomas H. Openshaw    207-973-4274      
Principal Investigator: Thomas H. Openshaw         
Eastern Maine Medical Center Recruiting
Bangor, Maine, United States, 04401
Contact: Thomas H. Openshaw    207-973-4274      
Principal Investigator: Thomas H. Openshaw         
United States, Maryland
Johns Hopkins University Recruiting
Baltimore, Maryland, United States, 21287-8936
Contact: Steven D. Gore    410-955-8804    jhcccro@jhmi.edu   
Principal Investigator: Steven D. Gore         
Walter Reed National Military Medical Center Recruiting
Bethesda, Maryland, United States, 20889-5600
Contact: David C. Van Echo    301-319-2100      
Principal Investigator: David C. Van Echo         
Union Hospital of Cecil County Recruiting
Elkton MD, Maryland, United States, 21921
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
United States, Massachusetts
Beth Israel Deaconess Medical Center Recruiting
Boston, Massachusetts, United States, 02215
Contact: David E. Avigan    617-667-9925      
Principal Investigator: David E. Avigan         
Tufts Medical Center Recruiting
Boston, Massachusetts, United States, 02111
Contact: Kellie A. Sprague    617-636-5000    ContactUsCancerCenter@TuftsMedicalCenter.org   
Principal Investigator: Kellie A. Sprague         
Caritas Saint Elizabeth's Medical Center Recruiting
Brighton, Massachusetts, United States, 02135-2997
Contact: Uma Narayanasami    617-789-2903      
Principal Investigator: Uma Narayanasami         
Baystate Medical Center Recruiting
Springfield, Massachusetts, United States, 01199
Contact: Syed S. Ali    413-794-3565    tamara.wrenn@baystatehealth.org   
Principal Investigator: Syed S. Ali         
United States, Michigan
Saint Joseph Mercy Hospital Recruiting
Ann Arbor, Michigan, United States, 48106-0995
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Michigan Cancer Research Consortium Community Clinical Oncology Program Recruiting
Ann Arbor, Michigan, United States, 48106
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Bronson Battle Creek Recruiting
Battle Creek, Michigan, United States, 49017
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Mecosta County Medical Center Recruiting
Big Rapids, Michigan, United States, 49307
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Oakwood Hospital Recruiting
Dearborn, Michigan, United States, 48124
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Wayne State University Recruiting
Detroit, Michigan, United States, 48202
Contact: Joseph P. Uberti    313-576-9363      
Principal Investigator: Joseph P. Uberti         
Saint John Hospital and Medical Center Recruiting
Detroit, Michigan, United States, 48236
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Genesys Hurley Cancer Institute Recruiting
Flint, Michigan, United States, 48503
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Genesys Regional Medical Center-West Flint Campus Recruiting
Flint, Michigan, United States, 48532
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Hurley Medical Center Recruiting
Flint, Michigan, United States, 48502
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Genesys Regional Medical Center Active, not recruiting
Grand Blanc, Michigan, United States, 48439
Spectrum Health at Butterworth Campus Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Grand Rapids Clinical Oncology Program Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Saint Mary's Health Care Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Allegiance Health Recruiting
Jackson, Michigan, United States, 49201
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Bronson Methodist Hospital Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
West Michigan Cancer Center Recruiting
Kalamazoo, Michigan, United States, 49007
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Borgess Medical Center Recruiting
Kalamazoo, Michigan, United States, 49001
Contact: Raymond S. Lord    269-373-7458      
Principal Investigator: Raymond S. Lord         
Sparrow Hospital Recruiting
Lansing, Michigan, United States, 48912
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Saint Mary Mercy Hospital Recruiting
Livonia, Michigan, United States, 48154
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Mercy Health Partners-Mercy Campus Recruiting
Muskegon, Michigan, United States, 49444
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Saint Joseph Mercy Oakland Recruiting
Pontiac, Michigan, United States, 48341-2985
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Saint Joseph Mercy Port Huron Recruiting
Port Huron, Michigan, United States, 48060
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Spectrum Health Reed City Hospital Recruiting
Reed City, Michigan, United States, 49677
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Saint Mary's of Michigan Recruiting
Saginaw, Michigan, United States, 48601
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
Providence Hospital Recruiting
Southfield, Michigan, United States, 48075
Contact: Howard R. Terebelo    248-849-5337    jaswinder.grewal@stjohn.org   
Principal Investigator: Howard R. Terebelo         
Munson Medical Center Recruiting
Traverse City, Michigan, United States, 49684
Contact: Gilbert D. Padula    616-685-5225      
Principal Investigator: Gilbert D. Padula         
Saint John Macomb-Oakland Hospital Recruiting
Warren, Michigan, United States, 48093
Contact: Christopher M. Reynolds    734-712-3456      
Principal Investigator: Christopher M. Reynolds         
United States, Minnesota
Sanford Clinic North-Bemidgi Recruiting
Bemidji, Minnesota, United States, 56601
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Essentia Health Saint Joseph's Medical Center Active, not recruiting
Brainerd, Minnesota, United States, 56401
Essentia Health Saint Mary's Medical Center Recruiting
Duluth, Minnesota, United States, 55805
Contact: Daniel A. Nikcevich    888-203-7267      
Principal Investigator: Daniel A. Nikcevich         
Essentia Health Duluth Clinic CCOP Recruiting
Duluth, Minnesota, United States, 55805
Contact: Daniel A. Nikcevich    888-203-7267      
Principal Investigator: Daniel A. Nikcevich         
Miller-Dwan Hospital Recruiting
Duluth, Minnesota, United States, 55805
Contact: Daniel A. Nikcevich    888-203-7267      
Principal Investigator: Daniel A. Nikcevich         
Lake Region Healthcare Corporation-Cancer Care Recruiting
Fergus Falls, Minnesota, United States, 56537
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Mayo Clinic Recruiting
Rochester, Minnesota, United States, 55905
Contact: James M. Foran    507-538-7623      
Principal Investigator: James M. Foran         
United States, Mississippi
University of Mississippi Medical Center Recruiting
Jackson, Mississippi, United States, 39216
Contact: Stephanie L. Elkins    601-815-6700      
Principal Investigator: Stephanie L. Elkins         
United States, Missouri
Saint Francis Medical Center Recruiting
Cape Girardeau, Missouri, United States, 63703
Contact: James L. Wade    217-876-4740    kcheek@dmhhs.org   
Principal Investigator: James L. Wade         
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: Geoffrey L. Uy    800-600-3606    info@siteman.wustl.edu   
Principal Investigator: Geoffrey L. Uy         
Saint Louis Cancer and Breast Institute-South City Recruiting
Saint Louis, Missouri, United States, 63109
Contact: Bethany G. Sleckman    913-948-5588      
Principal Investigator: Bethany G. Sleckman         
Saint Louis University Hospital Active, not recruiting
Saint Louis, Missouri, United States, 63110
Saint Louis-Cape Girardeau CCOP Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Bethany G. Sleckman    913-948-5588      
Principal Investigator: Bethany G. Sleckman         
Saint John's Mercy Medical Center Recruiting
Saint Louis, Missouri, United States, 63141
Contact: Bethany G. Sleckman    913-948-5588      
Principal Investigator: Bethany G. Sleckman         
United States, Montana
Hematology-Oncology Centers of the Northern Rockies PC Active, not recruiting
Billings, Montana, United States, 59102
Billings Clinic Recruiting
Billings, Montana, United States, 59107-7000
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Saint Vincent Healthcare Recruiting
Billings, Montana, United States, 59101
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Montana Cancer Consortium CCOP Recruiting
Billings, Montana, United States, 59101
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Bozeman Deaconess Cancer Center Recruiting
Bozeman, Montana, United States, 59715
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Bozeman Deaconess Hospital Recruiting
Bozeman, Montana, United States, 59715
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Saint James Community Hospital and Cancer Treatment Center Recruiting
Butte, Montana, United States, 59701
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Great Falls Clinic Active, not recruiting
Great Falls, Montana, United States, 59405
Benefis Healthcare- Sletten Cancer Institute Recruiting
Great Falls, Montana, United States, 59405
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Northern Montana Hospital Terminated
Havre, Montana, United States, 59501
Saint Peter's Community Hospital Recruiting
Helena, Montana, United States, 59601
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Kalispell Regional Medical Center Recruiting
Kalispell, Montana, United States, 59901
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Kalispell Medical Oncology Active, not recruiting
Kalispell, Montana, United States, 59901
Glacier Oncology PLLC Active, not recruiting
Kalispell, Montana, United States, 59901
Montana Cancer Specialists Recruiting
Missoula, Montana, United States, 59802
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Saint Patrick Hospital - Community Hospital Recruiting
Missoula, Montana, United States, 59802
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
United States, Nevada
Nevada Cancer Research Foundation CCOP Recruiting
Las Vegas, Nevada, United States, 89106
Contact: John A. Ellerton    702-731-8274      
Principal Investigator: John A. Ellerton         
United States, New Jersey
Cooper Hospital University Medical Center Recruiting
Camden, New Jersey, United States, 08103
Contact: Frank V. Beardell    302-733-6227      
Principal Investigator: Frank V. Beardell         
United States, New York
Winthrop University Hospital Recruiting
Mineola, New York, United States, 11501
Contact: Harry Staszewski    866-946-8476      
Principal Investigator: Harry Staszewski         
Memorial Sloan Kettering Cancer Center Recruiting
New York, New York, United States, 10065
Contact: Martin S. Tallman    212-639-7202    cancer@northwestern.edu   
Principal Investigator: Martin S. Tallman         
University of Rochester Recruiting
Rochester, New York, United States, 14642
Contact: Jonathan W. Friedberg    585-275-5830      
Principal Investigator: Jonathan W. Friedberg         
United States, North Carolina
Park Ridge Hospital Breast Health Center Recruiting
Hendersonville, North Carolina, United States, 28792
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Kinston Medical Specialists PA Recruiting
Kinston, North Carolina, United States, 28501
Contact: Peter R. Watson    252-559-2200      
Principal Investigator: Peter R. Watson         
United States, North Dakota
Roger Maris Cancer Center Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Sanford Clinic North-Fargo Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
Sanford Medical Center-Fargo Recruiting
Fargo, North Dakota, United States, 58122
Contact: Preston D. Steen    701-234-6161      
Principal Investigator: Preston D. Steen         
United States, Ohio
Akron General Medical Center Recruiting
Akron, Ohio, United States, 44307
Contact: Esther H. Rehmus    330-344-6348      
Principal Investigator: Esther H. Rehmus         
Summa Akron City Hospital Recruiting
Akron, Ohio, United States, 44304
Contact: Jennifer E. Payne    330-375-6101      
Principal Investigator: Jennifer E. Payne         
Summa Barberton Hospital Recruiting
Barberton, Ohio, United States, 44203
Contact: Jennifer E. Payne    330-375-6101      
Principal Investigator: Jennifer E. Payne         
Aultman Health Foundation Recruiting
Canton, Ohio, United States, 44710
Contact: Kisa E. Weeman    330-363-6891      
Principal Investigator: Kisa E. Weeman         
The Jewish Hospital Recruiting
Cincinnati, Ohio, United States, 45236
Contact: Edward R. Broun    513-686-5482      
Principal Investigator: Edward R. Broun         
MetroHealth Medical Center Withdrawn
Cleveland, Ohio, United States, 44109
Case Western Reserve University Recruiting
Cleveland, Ohio, United States, 44106
Contact: Hillard M. Lazarus    800-641-2422      
Principal Investigator: Hillard M. Lazarus         
Dayton CCOP Recruiting
Dayton, Ohio, United States, 45420
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Samaritan North Health Center Recruiting
Dayton, Ohio, United States, 45415
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Grandview Hospital Recruiting
Dayton, Ohio, United States, 45405
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Good Samaritan Hospital - Dayton Recruiting
Dayton, Ohio, United States, 45406
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Miami Valley Hospital Recruiting
Dayton, Ohio, United States, 45409
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Blanchard Valley Hospital Recruiting
Findlay, Ohio, United States, 45840
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Atrium Medical Center-Middletown Regional Hospital Recruiting
Franklin, Ohio, United States, 45005-1066
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Wayne Hospital Recruiting
Greenville, Ohio, United States, 45331
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Kettering Medical Center Recruiting
Kettering, Ohio, United States, 45429
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Saint Rita's Medical Center Recruiting
Lima, Ohio, United States, 45801
Contact: Henry Gerad    419-226-9617      
Principal Investigator: Henry Gerad         
Upper Valley Medical Center Recruiting
Troy, Ohio, United States, 45373
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
Clinton Memorial Hospital Terminated
Wilmington, Ohio, United States, 45177
Greene Memorial Hospital Recruiting
Xenia, Ohio, United States, 45385
Contact: Howard M. Gross    765-983-3000      
Principal Investigator: Howard M. Gross         
United States, Oklahoma
University of Oklahoma Health Sciences Center Recruiting
Oklahoma City, Oklahoma, United States, 73104
Contact: Carla Kurkjian    405-271-4272    julie-traylor@ouhsc.edu   
Principal Investigator: Carla Kurkjian         
United States, Oregon
Clackamas Radiation Oncology Center Recruiting
Clackamas, Oregon, United States, 97015
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Providence Milwaukie Hospital Recruiting
Milwaukie, Oregon, United States, 97222
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Providence Newberg Medical Center Recruiting
Newberg, Oregon, United States, 97132
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Providence Willamette Falls Medical Center Recruiting
Oregon City, Oregon, United States, 97045
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Providence Portland Medical Center Recruiting
Portland, Oregon, United States, 97213
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Providence Saint Vincent Medical Center Recruiting
Portland, Oregon, United States, 97225
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
Columbia River Oncology Program Recruiting
Portland, Oregon, United States, 97225
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
United States, Pennsylvania
Lehigh Valley Hospital Recruiting
Allentown, Pennsylvania, United States, 18105
Contact: Eliot L. Friedman    610-402-2273      
Principal Investigator: Eliot L. Friedman         
Lehigh Valley Hospital - Muhlenberg Recruiting
Bethlehem, Pennsylvania, United States, 18017
Contact: Eliot L. Friedman    610-402-2273      
Principal Investigator: Eliot L. Friedman         
Geisinger Medical Center Recruiting
Danville, Pennsylvania, United States, 17822-2001
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Geisinger Medical Center-Cancer Center Hazelton Recruiting
Hazleton, Pennsylvania, United States, 18201
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Penn State Milton S Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033-0850
Contact: David F. Claxton    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: David F. Claxton         
Lewistown Hospital Recruiting
Lewistown, Pennsylvania, United States, 17044
Contact: David F. Claxton    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: David F. Claxton         
Pennsylvania Hospital Withdrawn
Philadelphia, Pennsylvania, United States, 19107
Fox Chase Cancer Center Active, not recruiting
Philadelphia, Pennsylvania, United States, 19111-2497
Abramson Cancer Center of The University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Selina M. Luger    800-474-9892      
Principal Investigator: Selina M. Luger         
Hematology and Oncology Associates of North East Pennsylvania Withdrawn
Scranton, Pennsylvania, United States, 18508
Mount Nittany Medical Center Recruiting
State College, Pennsylvania, United States, 16803
Contact: David F. Claxton    717-531-3779    CTO@hmc.psu.edu   
Principal Investigator: David F. Claxton         
Geisinger Medical Group Recruiting
State College, Pennsylvania, United States, 16801
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
Geisinger Wyoming Valley Recruiting
Wilkes-Barre, Pennsylvania, United States, 18711
Contact: Edward J. Gorak    570-271-5251      
Principal Investigator: Edward J. Gorak         
York Hospital Recruiting
York, Pennsylvania, United States, 17405
Contact: Amir Tabatabai    877-441-7957      
Principal Investigator: Amir Tabatabai         
United States, South Carolina
AnMed Health Cancer Center Recruiting
Anderson, South Carolina, United States, 29621
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Saint Francis Hospital Recruiting
Greenville, South Carolina, United States, 29601
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Carolina Blood and Cancer Care Associates PA-Lancaster Recruiting
Lancaster, South Carolina, United States, 29720
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Carolina Blood and Cancer Care Associates PA Recruiting
Rock Hill, South Carolina, United States, 29732
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Upstate Carolina CCOP Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
Spartanburg Regional Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Charles E. Bowers    800-486-5941      
Principal Investigator: Charles E. Bowers         
United States, South Dakota
Medical X-Ray Center Active, not recruiting
Sioux Falls, South Dakota, United States, 57105
Sanford Cancer Center-Oncology Clinic Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Miroslaw A. Mazurczak    605-328-1367      
Principal Investigator: Miroslaw A. Mazurczak         
Sanford USD Medical Center - Sioux Falls Recruiting
Sioux Falls, South Dakota, United States, 57117-5134
Contact: Miroslaw A. Mazurczak    605-328-1367      
Principal Investigator: Miroslaw A. Mazurczak         
United States, Tennessee
Erlanger Medical Center Recruiting
Chattanooga, Tennessee, United States, 37403
Contact: Larry L. Schlabach    423-778-6947      
Principal Investigator: Larry L. Schlabach         
Jackson-Madison County General Hospital Recruiting
Jackson, Tennessee, United States, 38301
Contact: Brion V. Randolph    731-425-6865      
Principal Investigator: Brion V. Randolph         
Vanderbilt-Ingram Cancer Center Recruiting
Nashville, Tennessee, United States, 37232
Contact: Stephen A. Strickland    800-811-8480      
Principal Investigator: Stephen A. Strickland         
United States, Washington
Northwest Cancer Specialists Recruiting
Vancouver, Washington, United States, 98684
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
PeaceHealth Southwest Medical Center Recruiting
Vancouver, Washington, United States, 98664
Contact: Alison K. Conlin    503-215-6412      
Principal Investigator: Alison K. Conlin         
United States, West Virginia
West Virginia University Charleston Recruiting
Charleston, West Virginia, United States, 25304
Contact: Steven J. Jubelirer    304-388-9944      
Principal Investigator: Steven J. Jubelirer         
West Virginia University Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Michael D. Craig    304-293-2745    sfilburn@hsc.wvu.edu   
Principal Investigator: Michael D. Craig         
United States, Wisconsin
Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Green Bay Oncology at Saint Vincent Hospital Recruiting
Green Bay, Wisconsin, United States, 54301-3526
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Green Bay Oncology Limited at Saint Mary's Hospital Recruiting
Green Bay, Wisconsin, United States, 54303
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Gundersen Lutheran Recruiting
La Crosse, Wisconsin, United States, 54601
Contact: Kurt Oettel    608-775-2385    cancerctr@gundluth.org   
Principal Investigator: Kurt Oettel         
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Ryan J. Mattison    877-405-6866      
Principal Investigator: Ryan J. Mattison         
Holy Family Memorial Hospital Recruiting
Manitowoc, Wisconsin, United States, 54221
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Bay Area Medical Center Recruiting
Marinette, Wisconsin, United States, 54143
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Froedtert and the Medical College of Wisconsin Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Ehab L. Atallah    414-805-4380      
Principal Investigator: Ehab L. Atallah         
D N Greenwald Center Recruiting
Mukwonago, Wisconsin, United States, 53149
Contact: Timothy R. Wassenaar    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Oconomowoc Memorial Hospital-ProHealth Care Inc Recruiting
Oconomowoc, Wisconsin, United States, 53066-3896
Contact: Timothy R. Wassenaar    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Saint Nicholas Hospital Recruiting
Sheboygan, Wisconsin, United States, 53081
Contact: Gerald K. Bayer    800-432-6049      
Principal Investigator: Gerald K. Bayer         
Waukesha Memorial Hospital - ProHealth Care Recruiting
Waukesha, Wisconsin, United States, 53188
Contact: Timothy R. Wassenaar    262-928-7878      
Principal Investigator: Timothy R. Wassenaar         
Aurora Cancer Care-Milwaukee West Recruiting
Wauwatosa, Wisconsin, United States, 53226
Contact: Rubina Qamar    888-709-2080      
Principal Investigator: Rubina Qamar         
United States, Wyoming
Rocky Mountain Oncology Recruiting
Casper, Wyoming, United States, 82609
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
Welch Cancer Center Recruiting
Sheridan, Wyoming, United States, 82801
Contact: Benjamin T. Marchello    800-648-6274      
Principal Investigator: Benjamin T. Marchello         
India
Mayo Clinic Methodist Hospital Recruiting
Nagpur, India, 440 018
Contact: James M. Foran    507-538-7623      
Principal Investigator: James M. Foran         
Israel
Rambam Medical Center Recruiting
Haifa, Israel, 31096
Contact: Jacob M. Rowe    972-4-8541737    y_rozen@rambam.health.gov.il   
Principal Investigator: Jacob M. Rowe         
Shaare Zedek Medical Center Recruiting
Jerusalem, Israel, 91031
Contact: Jacob M. Rowe    972-4-8541737    y_rozen@rambam.health.gov.il   
Principal Investigator: Jacob M. Rowe         
Sponsors and Collaborators
Eastern Cooperative Oncology Group
Investigators
Principal Investigator: James Foran Eastern Cooperative Oncology Group
  More Information

No publications provided

Responsible Party: Eastern Cooperative Oncology Group
ClinicalTrials.gov Identifier: NCT02085408     History of Changes
Other Study ID Numbers: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, E2906, E2906, U10CA021115
Study First Received: March 11, 2014
Last Updated: September 16, 2014
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Leukemia
Leukemia, Myelomonocytic, Acute
Leukemia, Myelomonocytic, Chronic
Leukemia, Monocytic, Acute
Leukemia, Megakaryoblastic, Acute
Leukemia, Erythroblastic, Acute
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Cytarabine
Decitabine
Clofarabine
Daunorubicin
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Antineoplastic Agents
Therapeutic Uses
Antiviral Agents
Anti-Infective Agents
Immunosuppressive Agents

ClinicalTrials.gov processed this record on September 18, 2014